Chronic stress is a major driver of systemic inflammation and a contributor to the inflammation-depression loop that produces refractory psychiatric illness and accelerates cognitive aging. The biology is well-characterized. The clinical implication is that addressing chronic stress is anti-inflammatory medicine — not merely a wellness recommendation but a substrate-level intervention with measurable downstream effects on the inflammatory markers and the psychiatric outcomes that depend on them.
The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary stress-response system. Acute stress activates the axis: hypothalamic CRH → pituitary ACTH → adrenal cortisol → peripheral effects (glucose mobilization, immune modulation, metabolic shifts) → negative feedback that turns the axis off when the stressor resolves. This system is adaptive and protective in acute situations. In chronic activation — sustained psychological stress, chronic illness, sleep deprivation, persistent insecurity, traumatic exposure — the system dysregulates: the negative feedback becomes less effective, baseline cortisol rises, diurnal rhythm flattens, and the protective acute response becomes a chronic harmful state.
Chronic elevated cortisol produces neurobiological consequences. Hippocampal volume loss — sustained glucocorticoid exposure damages hippocampal neurons, reducing memory function and possibly contributing to dementia risk. Prefrontal cortex dysfunction — chronic stress impairs executive function, emotional regulation, and decision-making. Amygdala hyperreactivity — the threat-detection system becomes hyper-responsive, producing the anxiety-prone state that further amplifies stress signaling. The neurobiological signatures of chronic stress overlap substantially with the signatures of depression, anxiety, and accelerated cognitive aging.
The stress-inflammation connection runs through multiple pathways. Chronic cortisol elevation eventually produces glucocorticoid resistance in immune cells, paradoxically leading to inflammation rather than its suppression. Sympathetic nervous system overactivity activates inflammatory cascades. Sleep disruption from chronic stress reinforces inflammatory dysregulation. Behavioral consequences of chronic stress (poor diet, reduced exercise, increased alcohol, social withdrawal) compound the metabolic and inflammatory load. The patient with chronic unmanaged stress is in an inflammatory state by mechanism, not just by association.
The interventions that interrupt the loop include cognitive and behavioral approaches (CBT, mindfulness-based stress reduction, acceptance-based therapies) with substantial evidence for stress and depression and emerging evidence for inflammatory markers and cognitive trajectory. Autonomic regulation work — breathing protocols, HRV training, polyvagal-informed interventions — directly modulates the stress response. Sleep restoration is foundational. Exercise produces a complex but generally anti-stress and anti-inflammatory effect. Social connection and purpose work address the structural drivers of chronic stress. Pharmacological options include the standard psychiatric medications (with attention to which agents do or do not address the inflammatory dimension) and specific anti-stress interventions (beta blockers for autonomic load, adaptogenic compounds in some traditions, with varying evidence).
The longevity-psychiatry view of chronic stress is that it is not a soft variable. The patient who is chronically stressed at 50 has a substrate that drives both psychiatric illness and cognitive trajectory in the wrong direction. Addressing the stress is part of the clinical work, not separate from it — and the clinical interventions that work have evidence and protocols, not just generic wellness recommendations. The skilled clinical move is to take chronic stress seriously, characterize its drivers, and intervene with the same rigor applied to any other modifiable risk factor.